Answers are grounded in this paper and cite their sources.
Profiling ADC targets in cholangiocarcinoma shows high selectivity, indicating implications for cancer therapy development.
Antibody drug conjugates (ADCs) are clinically active in several cancers, but their relevance in cholangiocarcinoma (CCA) is undefined. We profiled 23 CCA tumors and found that TROP2 was highly expressed (82.6%) but also present in benign epithelium. NECTIN4 (65.2%) showed tumor-specific staining, supporting selectivity. B7-H3 (47.8%) and CLDN18.2 (13.0%) were less frequently positive. IDH1-mutant tumors demonstrated attenuated ADC target expression. These data provide rationale for evaluating ADC strategies in CCA.
No takes yet. Share an insight, caveat, or question.
Nakazawa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: